Dabigatran (Pradaxa)


Indications

Systemic Embolism Prevention in Nonvalvular Atrial Fibrillation (see Atrial Fibrillation)

Clinical Efficacy-General

Clinical Efficacy-Cost Effectiveness

Venous Thromboembolism (see Deep Venous Thrombosis and Acute Pulmonary Embolism)

Clinical Efficacy

Venous Thromboembolism Prophylaxis Post-Knee and Hip Replacement (see Deep Venous Thrombosis)

Clinical Efficacy


Pharmacology

Pharmacokinetics

Metabolism

Drug Interactions


Administration

PO Dosing

Hepatic Dose-Adjustment

Renal Dose-Adjustment

Venous Thromboembolism

Non-Valvular Atrial Fibrillation

Venous Thromboembolism Prophylaxis

Dose Adjustment for Obesity (2016 International Society of Thrombosis and Hemostasis Recommendations) (J Thromb Haemost, 2016) [MEDLINE]

Effect on Anticoagulation Tests

Conversion from/to Other Anticoagulants

Conversion from Dabigatran

Conversion to Dabigatran

Abrupt Discontinuation of Dabigatran


Periprocedural/Perioperative Management of Dabigatran Anticoagulation

Recommendations for Periprocedural/Perioperative Management of Dabigatran (American College of Chest Physicians Clinical Practice Guideline for the Perioperative Management of Antithrombotic Therapy) (Chest, 2022) [MEDLINE]


Reversal of Dabigatran Anticoagulation


Adverse Effects

Hemorrhagic Adverse Effects

General Comments

Post-Hip Replacement or Knee Replacement DVT Prophylaxis Trials

Atrial Fibrillation Trials

Venous Thrombembolism Trials

Comparative Rates of Hemorrhage Between Coumadin and Novel Oral Anticoagulants

Types of Hemorrhage

Other Adverse Effects


References

General

Indications

Atrial Fibrillation

Venous Thromboembolism

Administration

Administration in Specific Clinical Subsets of Patients